{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:46:22Z","timestamp":1792208782425,"version":"4.4.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R01AI143931-04"],"award-info":[{"award-number":["5R01AI143931-04"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>A family of Peptidyl-prolyl isomerases (PPIases), called Cyclophilins, localize to numerous intracellular and extracellular locations where they contribute to a variety of essential functions. We previously reported that non-immunosuppressive pan-cyclophilin inhibitor drugs like reconfilstat (CRV431) or NV556 decreased multiple aspects of non-alcoholic fatty liver disease (NAFLD) in mice under two different non-alcoholic steatohepatitis (NASH) mouse models. Both CRV431 and NV556 inhibit several cyclophilin isoforms, among which cyclophilin D (CypD) has not been previously investigated in this context. It is unknown whether it is necessary to simultaneously inhibit multiple cyclophilin family members to achieve therapeutic benefits or if loss-of-function of one is sufficient. Furthermore, narrowing down the isoform most responsible for a particular aspect of NAFLD\/NASH, such as hepatocellular carcinoma (HCC), would allow for more precise future therapies. Features of human diabetes-linked NAFLD\/NASH can be reliably replicated in mice by administering a single high dose of streptozotocin to disrupt pancreatic beta cells, in conjunction with a high sugar, high fat, high cholesterol western diet over the course of 30 weeks. Here we show that while both wild-type (WT) and Ppif-\/- CypD KO mice develop multipe severe NASH disease features under this model, the formation of HCC nodules was significantly blunted only in the CypD KO mice. Furthermore, of differentially expressed transcripts in a qPCR panel of select HCC-related genes, nearly all were downregulated in the CypD KO background. Cyclophilin inhibition is a promising and novel avenue of treatment for diet-induced NAFLD\/NASH. This study highlights the impact of CypD loss-of-function on the development of HCC, one of the most severe disease outcomes.<\/jats:p>","DOI":"10.1371\/journal.pone.0301711","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T17:28:47Z","timestamp":1712251727000},"page":"e0301711","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6092-6006","authenticated-orcid":true,"given":"Winston T.","family":"Stauffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bobardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daren R.","family":"Ure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6151-4764","authenticated-orcid":true,"given":"Philippe","family":"Gallay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"issue":"9491","key":"pone.0301711.ref001","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome\u2014a new worldwide definition","volume":"366","author":"KG Alberti","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"pone.0301711.ref002","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"R Loomba","year":"2021","journal-title":"Cell"},{"issue":"Suppl 1","key":"pone.0301711.ref003","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/liv.13299","article-title":"The epidemiology of non-alcoholic fatty liver disease","volume":"37","author":"S. Bellentani","year":"2017","journal-title":"Liver Int"},{"issue":"6","key":"pone.0301711.ref004","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"QM Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"20","key":"pone.0301711.ref005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205037","article-title":"Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products","volume":"20","author":"DH Fernando","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"pone.0301711.ref006","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"ZM Younossi","year":"2023","journal-title":"Hepatology"},{"key":"pone.0301711.ref007","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/JHC.S61146","article-title":"Hepatocellular carcinoma: a review","volume":"3","author":"J Balogh","year":"2016","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"pone.0301711.ref008","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbcan.2018.11.005","article-title":"Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans","volume":"1871","author":"K Chen","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"pone.0301711.ref009","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-018-0048-z","article-title":"Role of nonresolving inflammation in hepatocellular carcinoma development and progression","volume":"2","author":"LX Yu","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"pone.0301711.ref010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-3-642-03503-6_8","article-title":"Chronic inflammation and hepatocellular carcinoma","volume":"185","author":"MR Alison","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"pone.0301711.ref011","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3389\/fphar.2019.01129","article-title":"Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis","volume":"10","author":"J Kuo","year":"2019","journal-title":"Front Pharmacol"},{"issue":"12","key":"pone.0301711.ref012","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123041","article-title":"Novel Cyclophilin Inhibitor Decreases Cell Proliferation and Tumor Growth in Models of Hepatocellular Carcinoma","volume":"13","author":"S Simon Serrano","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"pone.0301711.ref013","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"HB El-Serag","year":"2012","journal-title":"Gastroenterology"},{"issue":"10","key":"pone.0301711.ref014","doi-asserted-by":"crossref","DOI":"10.3390\/v15102099","article-title":"The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity","volume":"15","author":"W Stauffer","year":"2023","journal-title":"Viruses"},{"issue":"2","key":"pone.0301711.ref015","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","article-title":"Hepatocellular carcinoma in the setting of alcohol-related liver disease","volume":"70","author":"N Ganne-Carrie","year":"2019","journal-title":"J Hepatol"},{"issue":"10","key":"pone.0301711.ref016","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"M Garcia-Cortes","year":"2020","journal-title":"Arch Toxicol"},{"issue":"6","key":"pone.0301711.ref017","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jhep.2011.10.027","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace","volume":"56","author":"G Baffy","year":"2012","journal-title":"J Hepatol"},{"key":"pone.0301711.ref018","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"JM Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"pone.0301711.ref019","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.cgh.2015.07.029","article-title":"Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes","volume":"13","author":"A Ahmed","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"pone.0301711.ref020","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.119.261099","article-title":"A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models","volume":"371","author":"J Kuo","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"pone.0301711.ref021","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811","volume":"343","author":"K Goto","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"pone.0301711.ref022","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jhep.2014.07.008","article-title":"Cyclophilin inhibition as potential therapy for liver diseases","volume":"61","author":"NV Naoumov","year":"2014","journal-title":"J Hepatol"},{"issue":"2","key":"pone.0301711.ref023","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.chembiol.2014.10.023","article-title":"Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection","volume":"22","author":"MJ Hansson","year":"2015","journal-title":"Chem Biol"},{"issue":"6206","key":"pone.0301711.ref024","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/337476a0","article-title":"Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins","volume":"337","author":"G Fischer","year":"1989","journal-title":"Nature"},{"issue":"6206","key":"pone.0301711.ref025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/337473a0","article-title":"Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin","volume":"337","author":"N Takahashi","year":"1989","journal-title":"Nature"},{"issue":"10","key":"pone.0301711.ref026","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.4049\/jimmunol.174.10.6030","article-title":"Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine","volume":"174","author":"J Colgan","year":"2005","journal-title":"J Immunol"},{"issue":"10","key":"pone.0301711.ref027","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.1038\/cddis.2013.410","article-title":"Cyclophilin A: a key player for human disease","volume":"4","author":"P Nigro","year":"2013","journal-title":"Cell Death Dis"},{"issue":"14","key":"pone.0301711.ref028","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.1128\/JVI.00393-11","article-title":"Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner","volume":"85","author":"TL Foster","year":"2011","journal-title":"J Virol"},{"issue":"3","key":"pone.0301711.ref029","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12026-011-8263-5","article-title":"Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents","volume":"52","author":"PA Gallay","year":"2012","journal-title":"Immunol Res"},{"issue":"6","key":"pone.0301711.ref030","doi-asserted-by":"crossref","first-page":"e0217433","DOI":"10.1371\/journal.pone.0217433","article-title":"The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice","volume":"14","author":"P Gallay","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"pone.0301711.ref031","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1073\/pnas.91.9.3931","article-title":"Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A","volume":"91","author":"ER Price","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0301711.ref032","article-title":"Cyclophilin B, a molecule chaperone, promotes adipogenesis in 3T3\u2011L1 preadipocytes via AKT\/mTOR pathway","volume":"51","author":"JS Yoon","year":"2023","journal-title":"Int J Mol Med"},{"issue":"20","key":"pone.0301711.ref033","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1111\/febs.15249","article-title":"Inorganic polyphosphate controls cyclophilin B-mediated collagen folding in osteoblast-like cells","volume":"287","author":"ML Khong","year":"2020","journal-title":"FEBS J"},{"issue":"3","key":"pone.0301711.ref034","doi-asserted-by":"crossref","first-page":"e0298211","DOI":"10.1371\/journal.pone.0298211","article-title":"Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced model","volume":"19","author":"WT Stauffer","year":"2024","journal-title":"PLoS One"},{"issue":"5","key":"pone.0301711.ref035","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1253\/circj.CJ-13-0321","article-title":"Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore","volume":"77","author":"JW Elrod","year":"2013","journal-title":"Circ J"},{"issue":"1","key":"pone.0301711.ref036","doi-asserted-by":"crossref","first-page":"12749","DOI":"10.1038\/s41598-017-13096-7","article-title":"Cyclophilin D ablation is associated with increased end-ischemic mitochondrial hexokinase activity","volume":"7","author":"R Nederlof","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0301711.ref037","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13105-018-0627-z","article-title":"CypD-mPTP axis regulates mitochondrial functions contributing to osteogenic dysfunction of MC3T3-E1 cells in inflammation","volume":"74","author":"X Gan","year":"2018","journal-title":"J Physiol Biochem"},{"issue":"8","key":"pone.0301711.ref038","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bbadis.2013.09.003","article-title":"Mitochondrial permeability transition pore is a potential drug target for neurodegeneration","volume":"1842","author":"VK Rao","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"34","key":"pone.0301711.ref039","doi-asserted-by":"crossref","first-page":"12005","DOI":"10.1073\/pnas.0505294102","article-title":"Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia","volume":"102","author":"AC Schinzel","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"pone.0301711.ref040","doi-asserted-by":"crossref","first-page":"14314","DOI":"10.1074\/jbc.M513297200","article-title":"Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells","volume":"281","author":"K Machida","year":"2006","journal-title":"J Biol Chem"},{"issue":"3","key":"pone.0301711.ref041","doi-asserted-by":"crossref","first-page":"F683","DOI":"10.1152\/ajprenal.00417.2018","article-title":"Cyclophilin D knockout protects the mouse kidney against cyclosporin A-induced oxidative stress","volume":"317","author":"J Klawitter","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"pone.0301711.ref042","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","article-title":"A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma","volume":"46","author":"M Fujii","year":"2013","journal-title":"Med Mol Morphol"},{"issue":"1","key":"pone.0301711.ref043","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0023677215571192","article-title":"The carbon tetrachloride model in mice","volume":"49","author":"D Scholten","year":"2015","journal-title":"Lab Anim"},{"issue":"7033","key":"pone.0301711.ref044","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nature03434","article-title":"Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death","volume":"434","author":"CP Baines","year":"2005","journal-title":"Nature"},{"issue":"10","key":"pone.0301711.ref045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4254\/wjh.v6.i10.716","article-title":"Targeting the insulin-like growth factor pathway in hepatocellular carcinoma","volume":"6","author":"M Enguita-German","year":"2014","journal-title":"World J Hepatol"},{"key":"pone.0301711.ref046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/0471141755.ph0547s70","article-title":"Streptozotocin-Induced Diabetic Models in Mice and Rats","volume":"70","author":"BL Furman","year":"2015","journal-title":"Curr Protoc Pharmacol"},{"issue":"1","key":"pone.0301711.ref047","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","article-title":"Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma","volume":"39","author":"J Feng","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"pone.0301711.ref048","doi-asserted-by":"crossref","first-page":"939588","DOI":"10.3389\/fonc.2022.939588","article-title":"Cyclophilin D: Guardian or Executioner for Tumor Cells?","volume":"12","author":"L Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"pone.0301711.ref049","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1158\/0008-5472.CAN-03-0476","article-title":"Cyclophilin D, a component of the permeability transition-pore, is an apoptosis repressor","volume":"64","author":"A Schubert","year":"2004","journal-title":"Cancer Res"},{"issue":"7","key":"pone.0301711.ref050","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.cell.2012.05.014","article-title":"p53 opens the mitochondrial permeability transition pore to trigger necrosis","volume":"149","author":"AV Vaseva","year":"2012","journal-title":"Cell"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0301711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T17:29:18Z","timestamp":1712251758000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0301711"}},"subtitle":[],"editor":[{"given":"Vadim","family":"Ten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0301711","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}